160 related articles for article (PubMed ID: 37046413)
21. Surgical view of the treatment of patients with hepatoblastoma: results from the first prospective trial of the International Society of Pediatric Oncology Liver Tumor Study Group.
Schnater JM; Aronson DC; Plaschkes J; Perilongo G; Brown J; Otte JB; Brugieres L; Czauderna P; MacKinlay G; Vos A
Cancer; 2002 Feb; 94(4):1111-20. PubMed ID: 11920482
[TBL] [Abstract][Full Text] [Related]
22. Is multifocality a prognostic factor in childhood hepatoblastoma?
Saettini F; Conter V; Provenzi M; Rota M; Giraldi E; Foglia C; Cavalleri L; D'Antiga L
Pediatr Blood Cancer; 2014 Sep; 61(9):1593-7. PubMed ID: 24757164
[TBL] [Abstract][Full Text] [Related]
23. Tumor necrosis predicts survival following neo-adjuvant chemotherapy for hepatoblastoma.
Venkatramani R; Wang L; Malvar J; Dias D; Sposto R; Malogolowkin MH; Mascarenhas L
Pediatr Blood Cancer; 2012 Sep; 59(3):493-8. PubMed ID: 22190448
[TBL] [Abstract][Full Text] [Related]
24. Treatment of unresectable and metastatic hepatoblastoma: a pediatric oncology group phase II study.
Katzenstein HM; London WB; Douglass EC; Reynolds M; Plaschkes J; Finegold MJ; Bowman LC
J Clin Oncol; 2002 Aug; 20(16):3438-44. PubMed ID: 12177104
[TBL] [Abstract][Full Text] [Related]
25. Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach--results of the first prospective study of the International Society of Pediatric Oncology.
Pritchard J; Brown J; Shafford E; Perilongo G; Brock P; Dicks-Mireaux C; Keeling J; Phillips A; Vos A; Plaschkes J
J Clin Oncol; 2000 Nov; 18(22):3819-28. PubMed ID: 11078495
[TBL] [Abstract][Full Text] [Related]
26. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children's Cancer Group and the Pediatric Oncology Group.
Ortega JA; Douglass EC; Feusner JH; Reynolds M; Quinn JJ; Finegold MJ; Haas JE; King DR; Liu-Mares W; Sensel MG; Krailo MD
J Clin Oncol; 2000 Jul; 18(14):2665-75. PubMed ID: 10894865
[TBL] [Abstract][Full Text] [Related]
27. Tumor rupture in hepatoblastoma: A high risk factor?
Pondrom M; Pariente D; Mallon B; Taque S; Branchereau S; Chardot C; Laithier V; Tabone MD; Lejeune J; Faure-Conter C; Saumet L; Vérité C; Aerts I; Brugières L; Fresneau B
Pediatr Blood Cancer; 2020 Sep; 67(9):e28549. PubMed ID: 32618436
[TBL] [Abstract][Full Text] [Related]
28. Feasibility of dose-dense cisplatin-based chemotherapy in Japanese children with high-risk hepatoblastoma: Analysis of the JPLT3-H pilot study.
Watanabe K; Mori M; Hishiki T; Yokoi A; Ida K; Yano M; Fujimura J; Nogami Y; Iehara T; Hoshino K; Inoue T; Tanaka Y; Miyazaki O; Takimoto T; Yoshimura K; Hiyama E
Pediatr Blood Cancer; 2022 Feb; 69(2):e29389. PubMed ID: 34606680
[TBL] [Abstract][Full Text] [Related]
29. Efficiency and toxicity of ifosfamide, cisplatin and doxorubicin in the treatment of childhood hepatoblastoma. Study Committee of the Cooperative Paediatric Liver Tumour Study HB89 of the German Society for Paediatric Oncology and Haematology.
von Schweinitz D; Byrd DJ; Hecker H; Weinel P; Bode U; Bürger D; Erttmann R; Harms D; Mildenberger H
Eur J Cancer; 1997 Jul; 33(8):1243-9. PubMed ID: 9301450
[TBL] [Abstract][Full Text] [Related]
30. Single-agent cisplatin treatment of children with high-risk hepatoblastoma.
Zhang YT; Feng LH; Zhong XD; Wang LZ; Chang J
J Pediatr Hematol Oncol; 2014 May; 36(4):271-5. PubMed ID: 24309602
[TBL] [Abstract][Full Text] [Related]
31. Prognostic implications of serum alpha-fetoprotein response during treatment of hepatoblastoma.
Koh KN; Park M; Kim BE; Bae KW; Kim KM; Im HJ; Seo JJ
Pediatr Blood Cancer; 2011 Oct; 57(4):554-60. PubMed ID: 21370433
[TBL] [Abstract][Full Text] [Related]
32. Fibrolamellar variant of hepatocellular carcinoma does not have a better survival than conventional hepatocellular carcinoma--results and treatment recommendations from the Childhood Liver Tumour Strategy Group (SIOPEL) experience.
Weeda VB; Murawski M; McCabe AJ; Maibach R; Brugières L; Roebuck D; Fabre M; Zimmermann A; Otte JB; Sullivan M; Perilongo G; Childs M; Brock P; Zsíros J; Plaschkes J; Czauderna P; Aronson DC
Eur J Cancer; 2013 Aug; 49(12):2698-704. PubMed ID: 23683550
[TBL] [Abstract][Full Text] [Related]
33. Current chemotherapeutic approaches for hepatoblastoma.
Watanabe K
Int J Clin Oncol; 2013 Dec; 18(6):955-61. PubMed ID: 24052132
[TBL] [Abstract][Full Text] [Related]
34. [Treatment outcome of 100 patients with hepatoblastoma based on a new risk stratification].
Zhen ZZ; Liu JC; Zhou L; Xu Z; Zhang ZC; Sun FF; Lu SY; Zhu J; Wang J; Huang JT; Sun XF
Zhonghua Zhong Liu Za Zhi; 2021 Feb; 43(2):228-232. PubMed ID: 33601490
[No Abstract] [Full Text] [Related]
35. Characterization of Pulmonary Metastases in Children With Hepatoblastoma Treated on Children's Oncology Group Protocol AHEP0731 (The Treatment of Children With All Stages of Hepatoblastoma): A Report From the Children's Oncology Group.
O'Neill AF; Towbin AJ; Krailo MD; Xia C; Gao Y; McCarville MB; Meyers RL; McGahren ED; Tiao GM; Dunn SP; Langham MR; Weldon CB; Finegold MJ; Ranganathan S; Furman WL; Malogolowkin M; Rodriguez-Galindo C; Katzenstein HM
J Clin Oncol; 2017 Oct; 35(30):3465-3473. PubMed ID: 28892430
[TBL] [Abstract][Full Text] [Related]
36. Carboplatin-epirubicin regimen for the treatment of hepatoblastoma.
Blouin P; Brugières L; Tabone MD; Leverger G; Rubie H; Branchereau S; De Kraker J
Pediatr Blood Cancer; 2004 Feb; 42(2):149-54. PubMed ID: 14752879
[TBL] [Abstract][Full Text] [Related]
37. Prognostic stratification for children with hepatoblastoma: the SIOPEL experience.
Maibach R; Roebuck D; Brugieres L; Capra M; Brock P; Dall'Igna P; Otte JB; De Camargo B; Zsiros J; Zimmermann A; Aronson D; Childs M; Scopinaro M; Morland B; Plaschkes J; Czauderna P; Perilongo G
Eur J Cancer; 2012 Jul; 48(10):1543-9. PubMed ID: 22244829
[TBL] [Abstract][Full Text] [Related]
38. Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children's Oncology Group, multicentre, phase 3 trial.
Katzenstein HM; Langham MR; Malogolowkin MH; Krailo MD; Towbin AJ; McCarville MB; Finegold MJ; Ranganathan S; Dunn S; McGahren ED; Tiao GM; O'Neill AF; Qayed M; Furman WL; Xia C; Rodriguez-Galindo C; Meyers RL
Lancet Oncol; 2019 May; 20(5):719-727. PubMed ID: 30975630
[TBL] [Abstract][Full Text] [Related]
39. Recent improvement in survival outcomes and reappraisal of prognostic factors in hepatoblastoma.
Koh KN; Namgoong JM; Yoon HM; Cho YA; Choi SH; Shin J; Kang SH; Suh JK; Kim H; Oh SH; Kim KM; Kim DY; Im HJ
Cancer Med; 2021 May; 10(10):3261-3273. PubMed ID: 33939313
[TBL] [Abstract][Full Text] [Related]
40. Outcome of hepatoblastomas treated using the Japanese Study Group for Pediatric Liver Tumor (JPLT) protocol-2: report from the JPLT.
Hishiki T; Matsunaga T; Sasaki F; Yano M; Ida K; Horie H; Kondo S; Watanabe K; Oue T; Tajiri T; Kamimatsuse A; Ohnuma N; Hiyama E
Pediatr Surg Int; 2011 Jan; 27(1):1-8. PubMed ID: 20922397
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
